Hims & Hers Health, Inc. (HIMS) SEC Filings & Earnings Calls

Gross margin compression from 76% to 64% due to product mix and international expansion.

“Gross margin was 64% for the second quarter of 2026 compared to 76% for the second quarter of 2025” · word for word

Net loss of $86.3M vs net income of $42.5M in prior year, driven by investment in growth.

“Net loss was $86.3 million for the second quarter of 2026 compared to net income of $42.5 million for the second quarter of 2025” · word for word

Negative free cash flow persists, though slightly improved.

“Free Cash Flow was $(68.2) million for the second quarter of 2026 compared to $(69.4) million for the second quarter of 2025” · word for word

Regulatory action against compounded GLP-1s

“In February 2026, the FDA issued a statement indicating that the agency intends to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs that are being mass-marketed as similar alternatives to FDA-approved drugs. We were directly named in the FDA Statement. Also in February 2026, the General Counsel of HHS iss” · word for word

Strategic shift execution risk

“Customers who previously accessed compounded alternatives may be unwilling or unable to transition to branded therapies, which could adversely affect demand, conversion rates, and revenue. In addition, our margins may be impacted by the cost of procuring branded medications and limitations on our ability to pass through price increases.” · word for word

Competitive pressure from large players

“We operate in highly competitive markets and face competition from large, well-established healthcare providers, traditional retailers, pharmaceutical providers, and technology companies with significant resources.” · word for word

Key accounting officer departure; potential for temporary disruption in financial reporting oversight.

“Resignation of CAO/PAO; advisory agreement in place to ensure continuity.”

Convertible notes may dilute existing shareholders if converted; capped calls offset dilution only up to cap price.

“The initial conversion rate is 33.8590 shares of the Company's Class A common stock per $1,000 principal amount of Notes”

Potential dilution from convertible notes if converted.

“0.00% Convertible Senior Notes due 2032”

Regulatory action on compounded GLP-1s

“In February 2026, the FDA issued a statement indicating that the agency intends to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs that are being mass-marketed as similar alternatives to FDA-approved drugs. We were directly named in the FDA Statement. Also in February 2026, the General Counsel of HHS iss” · word for word

Margin pressure from shift to branded GLP-1s

“In addition, our margins may be impacted by the cost of procuring branded medications and limitations on our ability to pass through price increases.” · word for word

Customer retention risk during GLP-1 transition

“Customers who previously accessed compounded alternatives may be unwilling or unable to transition to branded therapies, which could adversely affect demand, conversion rates, and revenue.” · word for word

Supply chain risk for branded GLP-1s

“Further, our reliance on third-party manufacturers and supply chains for branded GLP-1 products exposes us to potential supply disruptions, pricing changes, and contractual limitations outside of our control.” · word for word

Gross margin compression due to GLP-1 product mix shift; net loss in Q1.

“Gross margin declined from 73% to 65%; net loss of $92.1M.”

Gross Margin Compression

“Our gross margin was 74% for the year, compared to 79% for 2024.” · word for word

Capex Intensity

“Less: purchases of property, equipment, and intangible assets in investing activities ... (226,045) ... (41,655)” · word for word

Controlled Company Governance

“We are a 'controlled company' within the meaning of the corporate governance standards of the New York Stock Exchange ('NYSE') because Mr. Dudum beneficially owns shares ... representing more than 50% of the total voting power” · word for word

Transition risk: existing compounded GLP-1 patients may be lost if they do not transition to branded medications.

“existing patients will have the opportunity to transition to FDA-approved medicines when determined clinically appropriate” · word for word

Free cash flow declined significantly due to capex and working capital

“Free Cash Flow was $57.4 million for the year ended December 31, 2025 compared to $198.3 million for the year ended December 31, 2024.” · word for word

Guidance assumes continued access to compounded semaglutide

“Guidance assumes the ongoing ability to provide access to compounded semaglutide through our platform, and no changes to our current business relationships.”

FDA/DOJ Investigation Risk

“Also in February 2026, the General Counsel of HHS issued a statement on X indicating that HHS had referred the Company to the Department of Justice (the 'DOJ') for investigation for potential violations of the FDCA and applicable Title 18 provisions.” · word for word

Compounded GLP-1 Regulatory Risk

“In February 2026, the FDA issued a statement (the 'FDA Statement') indicating that the agency intends to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs that are being mass-marketed as similar alternatives to FDA-approved drugs. We were directly named in the FDA Statement.” · word for word

Semaglutide Shortage Resolution Impact

“On February 21, 2025, the FDA resolved the semaglutide shortage. Resolution of the shortage limits our ability to use 503B outsourcing facilities to provide access to compounded semaglutide on our platform.” · word for word

Integration risk and regulatory approvals required for closing.

“The acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to close during the middle of calendar year 2026.” · word for word

GLP-1 supply and regulatory risk

“Resolution of the shortage has constrained and is expected to continue to constrain our ability to continue providing access to compounded semaglutide on our platform.” · word for word

Corporate practice of medicine risk

“If our arrangements are deemed to be inconsistent with any applicable government entity’s interpretation of a law or regulation prohibiting the corporate practice of medicine, a fee-splitting law, or similar regulatory prohibitions, we would need to restructure the arrangements with the Affiliated Medical Groups to create a compliant arrangement or terminate” · word for word

Marketing regulatory risk

“For example, in 2025, Meta implemented changes to the use of certain types of health-related data for ad targeting purposes.” · word for word

Competition risk

“We operate in highly competitive markets and face competition from large, well-established healthcare providers, traditional retailers, pharmaceutical providers, and technology companies with significant resources.” · word for word

Gross margin decline due to product mix shift.

“Gross margin was 74% for the third quarter of 2025 compared to 79% for the third quarter of 2024.” · word for word

Potential partnership with Novo Nordisk may not materialize.

“Discussions are ongoing, no definitive agreement has been executed with Novo Nordisk, and there is a possibility that no definitive agreement may ever be executed.” · word for word